$PIRS
PIERIS PHARMACEUTICALS, INC. Stock $pirs

$pirs Overview Financials Valuation SEC Filings Company Website

2019 Q2 Form 10-Q Financial Statement

#000158364819000021 Filed on May 10, 2019

Income Statement

Concept	2019 Q2	2019 Q1	2018 Q1
Revenue	$5.332M	$8.545M	$4.152M
YoY Change	-54.39%	105.8%	209.16%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.190M	$4.930M	$4.350M
YoY Change	-12.34%	13.33%	9.02%
% of Gross Profit
Research & Development	$13.37M	$14.30M	$7.936M
YoY Change	46.07%	80.14%	48.06%
% of Gross Profit
Depreciation & Amortization	$40.00K	$166.0K	$134.0K
YoY Change	-73.33%	23.88%	34.0%
% of Gross Profit
Operating Expenses	$17.56M	$19.23M	$12.29M
YoY Change	26.04%	56.48%	31.44%
Operating Profit	-$12.23M	-$10.68M	-$8.136M
YoY Change	445.25%	31.31%	1.62%
Interest Expense	$449.0K	$506.0K	$325.0K
YoY Change	-32.18%	55.69%
% of Operating Profit
Other Income/Expense, Net	$23.00K	-$171.0K	-$903.0K
YoY Change	-98.13%	-81.06%	-7625.0%
Pretax Income	-$11.76M	-$10.35M	-$8.714M
YoY Change	3249.86%	18.75%	9.01%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$11.76M	-$10.35M	-$8.714M
YoY Change	5692.12%	18.75%	9.01%
Net Earnings / Revenue	-220.52%	-121.1%	-209.87%
Basic Earnings Per Share
Diluted Earnings Per Share	-$239.0K	-$203.5K	-$174.0K
COMMON SHARES
Basic Shares Outstanding	49.17M shares	49.15M shares	53.86M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q2	2019 Q1	2018 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$99.70M	$110.8M	$159.6M
YoY Change	-33.97%	-30.58%	189.13%
Cash & Equivalents	$54.90M	$52.09M	$109.5M
Short-Term Investments	$44.80M	$58.70M	$50.10M
Other Short-Term Assets	$4.600M	$6.400M	$3.200M
YoY Change	48.39%	100.0%	-8.57%
Inventory
Prepaid Expenses
Receivables	$7.174M	$7.128M	$3.309M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$111.5M	$124.3M	$166.1M
YoY Change	-28.82%	-25.17%	182.66%
LONG-TERM ASSETS
Property, Plant & Equipment	$7.888M	$4.893M	$4.445M
YoY Change	71.59%	10.08%	48.51%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments			$2.600M
YoY Change
Other Assets	$11.49M	$2.030M	$130.0K
YoY Change	8806.98%	1461.54%	3.02%
Total Long-Term Assets	$19.38M	$18.89M	$7.158M
YoY Change	257.13%	163.91%	129.48%
TOTAL ASSETS
Total Short-Term Assets	$111.5M	$124.3M	$166.1M
Total Long-Term Assets	$19.38M	$18.89M	$7.158M
Total Assets	$130.8M	$143.2M	$173.2M
YoY Change	-19.25%	-17.35%	179.98%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.031M	$3.728M	$1.934M
YoY Change	27.0%	92.76%	-41.7%
Accrued Expenses	$8.491M	$9.216M	$6.578M
YoY Change	86.12%	40.1%	122.31%
Deferred Revenue	$28.41M	$28.18M
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$40.93M	$41.13M	$54.76M
YoY Change	-21.79%	-24.9%	378.5%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$12.32M	$27.00K	$37.00K
YoY Change	33189.19%	-27.03%	-12.08%
Total Long-Term Liabilities	$12.32M	$27.00K	$37.00K
YoY Change	33189.19%	-27.03%	-12.08%
TOTAL LIABILITIES
Total Short-Term Liabilities	$40.93M	$41.13M	$54.76M
Total Long-Term Liabilities	$12.32M	$27.00K	$37.00K
Total Liabilities	$111.4M	$104.9M	$122.5M
YoY Change	4.36%	-14.41%	179.53%
SHAREHOLDERS EQUITY
Retained Earnings	-$170.8M	-$148.7M	-$129.0M
YoY Change	32.18%	15.25%	16.6%
Common Stock	$193.0M	$191.3M	$185.7M
YoY Change	3.14%	3.01%	42.68%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$19.49M	$30.16M	$50.69M
YoY Change
Total Liabilities & Shareholders Equity	$130.8M	$143.2M	$173.2M
YoY Change	-19.25%	-17.35%	179.98%

Cashflow Statement

Concept	2019 Q2	2019 Q1	2018 Q1
OPERATING ACTIVITIES
Net Income	-$11.76M	-$10.35M	-$8.714M
YoY Change	5692.12%	18.75%	9.01%
Depreciation, Depletion And Amortization	$40.00K	$166.0K	$134.0K
YoY Change	-73.33%	23.88%	34.0%
Cash From Operating Activities	-$10.73M	-$15.11M	$31.34M
YoY Change	19.35%	-148.21%	21.61%
INVESTING ACTIVITIES
Capital Expenditures	-$930.0K	$121.0K	$414.0K
YoY Change	132.5%	-70.77%	131.28%
Acquisitions
YoY Change
Other Investing Activities	$13.85M	-$5.200M	-$7.880M
YoY Change	-128.63%	-34.01%
Cash From Investing Activities	$12.92M	-$5.316M	-$8.293M
YoY Change	-126.49%	-35.9%	4507.22%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$0.00	$47.21M
YoY Change		-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	280.0K	$0.00	$48.16M
YoY Change	300.0%	-100.0%
NET CHANGE
Cash From Operating Activities	-10.73M	-$15.11M	$31.34M
Cash From Investing Activities	12.92M	-$5.316M	-$8.293M
Cash From Financing Activities	280.0K	$0.00	$48.16M
Net Change In Cash	2.470M	-$22.77M	$71.64M
YoY Change	-104.28%	-131.79%	179.96%
FREE CASH FLOW
Cash From Operating Activities	-$10.73M	-$15.11M	$31.34M
Capital Expenditures	-$930.0K	$121.0K	$414.0K
Free Cash Flow	-$9.800M	-$15.23M	$30.93M
YoY Change	14.09%	-149.24%	20.84%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2019Q1	dei	Amendment Flag AmendmentFlag	false
CY2019Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2019Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2019Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
CY2019Q1	dei	Document Period End Date DocumentPeriodEndDate	2019-03-31
CY2019Q1	dei	Document Type DocumentType	10-Q
CY2019Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001583648
CY2019Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	49173094	shares
CY2019Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2019Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2019Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2019Q1	dei	Entity Registrant Name EntityRegistrantName	PIERIS PHARMACEUTICALS, INC.
CY2019Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2019Q1	dei	Trading Symbol TradingSymbol	PIRS
CY2018Q4	pirs	Accrued License Obligations AccruedLicenseObligations	2523000	USD
CY2019Q1	pirs	Accrued License Obligations AccruedLicenseObligations	2520000	USD
CY2018Q4	pirs	Accrued Research And Development Costs AccruedResearchAndDevelopmentCosts	943000	USD
CY2019Q1	pirs	Accrued Research And Development Costs AccruedResearchAndDevelopmentCosts	2399000	USD
CY2018Q4	pirs	Accrued Tax Audit And Legal Fees AccruedTaxAuditAndLegalFees	378000	USD
CY2019Q1	pirs	Accrued Tax Audit And Legal Fees AccruedTaxAuditAndLegalFees	616000	USD
CY2019Q1	pirs	Additionsto Contractwith Customer Liability AdditionstoContractwithCustomerLiability	0	USD
CY2018Q4	pirs	Cash Equivalents And Investments CashEquivalentsAndInvestments	71941000	USD
CY2019Q1	pirs	Cash Equivalents And Investments CashEquivalentsAndInvestments	64415000	USD
CY2018Q1	pirs	Property And Equipment Included In Accounts Payable PropertyAndEquipmentIncludedInAccountsPayable	65000	USD
CY2019Q1	pirs	Property And Equipment Included In Accounts Payable PropertyAndEquipmentIncludedInAccountsPayable	0	USD
CY2018Q1	pirs	Revenuefrom Collaborative Arrangementexcluding Revenuefrom Contractwith Customer RevenuefromCollaborativeArrangementexcludingRevenuefromContractwithCustomer	617000	USD
CY2019Q1	pirs	Revenuefrom Collaborative Arrangementexcluding Revenuefrom Contractwith Customer RevenuefromCollaborativeArrangementexcludingRevenuefromContractwithCustomer	1011000	USD
CY2018Q1	pirs	Stock Issued During Period Value Conversionof Preferred Stock StockIssuedDuringPeriodValueConversionofPreferredStock	0	USD
CY2019Q1	pirs	Stock Issued During Period Value Conversionof Preferred Stock StockIssuedDuringPeriodValueConversionofPreferredStock	0	USD
CY2018Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	9114000	USD
CY2019Q1	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	9216000	USD
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3350000	USD
CY2019Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	3728000	USD
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2701000	USD
CY2019Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	7128000	USD
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9114000	USD
CY2019Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9216000	USD
CY2018Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1945000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	135382000	USD
CY2019Q1	us-gaap	Assets Current AssetsCurrent	124286000	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1004000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1290000	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	3374000	USD
CY2018Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14700000	shares
CY2019Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	21600000	shares
CY2018Q4	us-gaap	Assets Assets	141341000	USD
CY2019Q1	us-gaap	Assets Assets	131048000	USD
CY2019Q1	us-gaap	Assets Assets	143177000	USD
CY2019Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1259000	USD
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3366000	USD
CY2019Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3277000	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2982000	USD
CY2019Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2056000	USD
CY2018Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	189929000	USD
CY2019Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	191224000	USD
CY2019Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	191000	USD
CY2019Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2019Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	58494000	USD
CY2019Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	58685000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	74867000	USD
CY2019Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	52094000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	110800000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	37878000	USD
CY2018Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	109521000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	74867000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	52094000	USD
CY2018Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	71643000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-22773000	USD
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2019Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	54151219	shares
CY2019Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	49151219	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	54151219	shares
CY2019Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	49151219	shares
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	54000	USD
CY2019Q1	us-gaap	Common Stock Value CommonStockValue	49000	USD
CY2018Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9992000	USD
CY2019Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9422000	USD
CY2018Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	35612000	USD
CY2019Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	28181000	USD
CY2018Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	53303000	USD
CY2019Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	59734000	USD
CY2019Q1	us-gaap	Cumulative Effect Of New Accounting Principle In Period Of Adoption CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	-1641000	USD
CY2019Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	56780000	USD
CY2019Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	4300000	USD
CY2019Q1	us-gaap	Increase Decrease In Operating Capital IncreaseDecreaseInOperatingCapital	5918000	USD
CY2018Q1	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	-200000	USD
CY2019Q1	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	USD
CY2018Q1	us-gaap	Depreciation Depreciation	134000	USD
CY2019Q1	us-gaap	Depreciation Depreciation	166000	USD
CY2018Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.17
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.20
CY2018Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	438000	USD
CY2019Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-2349000	USD
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2380000	USD
CY2019Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1083000	USD
CY2018Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4352000	USD
CY2019Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4932000	USD
CY2018Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8714000	USD
CY2019Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-10348000	USD
CY2018Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2019Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2018Q1	us-gaap	Increase Decrease In Operating Capital IncreaseDecreaseInOperatingCapital	-38907000	USD
CY2018Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	325000	USD
CY2019Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	506000	USD
CY2018Q4	us-gaap	Liabilities Liabilities	101406000	USD
CY2019Q1	us-gaap	Liabilities Liabilities	100886000	USD
CY2019Q1	us-gaap	Liabilities Liabilities	104883000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	141341000	USD
CY2019Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	131048000	USD
CY2019Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	143177000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	48076000	USD
CY2019Q1	us-gaap	Liabilities Current LiabilitiesCurrent	41125000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	48159000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-8293000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5316000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	31339000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-15108000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-8714000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-10348000	USD
CY2018Q1	us-gaap	Operating Expenses OperatingExpenses	12288000	USD
CY2019Q1	us-gaap	Operating Expenses OperatingExpenses	19228000	USD
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-8136000	USD
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-10683000	USD
CY2018Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	945000	USD
CY2019Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1339000	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	910000	USD
CY2019Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1869000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent	100000	USD
CY2018Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	11479000	USD
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	27000	USD
CY2019Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2030000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-697000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	240000	USD
CY2019Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	27000	USD
CY2018Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-8000	USD
CY2019Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	298000	USD
CY2018Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-903000	USD
CY2019Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-171000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-747000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	686000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-531000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	240000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-581000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	686000	USD
CY2018Q1	us-gaap	Other Income OtherIncome	91000	USD
CY2019Q1	us-gaap	Other Income OtherIncome	0	USD
CY2019Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	8037000	USD
CY2018Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	414000	USD
CY2019Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	121000	USD
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000	shares
CY2019Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000	shares
CY2019Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	7907	shares
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4574000	USD
CY2019Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6379000	USD
CY2019Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5290000	USD
CY2018Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	47207000	USD
CY2019Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2018Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	3600000	USD
CY2019Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	2842000	USD
CY2018Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	826000	USD
CY2019Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2018Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	126000	USD
CY2019Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8415000	USD
CY2019Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8170000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5049000	USD
CY2019Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4893000	USD
CY2018Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7936000	USD
CY2019Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14296000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-147066000	USD
CY2019Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-159055000	USD
CY2019Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-148707000	USD
CY2018Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3444000	USD
CY2019Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7534000	USD
CY2018Q1	us-gaap	Revenues Revenues	4152000	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	50693000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	39935000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	30162000	USD
CY2019Q1	us-gaap	Revenues Revenues	8545000	USD
CY2018Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1004000	USD
CY2019Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1290000	USD
CY2018Q4	us-gaap	Short Term Investments ShortTermInvestments	53240000	USD
CY2019Q1	us-gaap	Short Term Investments ShortTermInvestments	58685000	USD
CY2018Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	126000	USD
CY2018Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	47207000	USD
CY2018Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	826000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	11522000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	38294000	USD
CY2018Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-697000	USD
CY2019Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	330000	USD
CY2018Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	50046000	shares
CY2019Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	50873000	shares
CY2019Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has no financial instruments with off‑balance sheet risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements. Financial instruments that subject Pieris to concentrations of credit risk include cash and cash equivalents, investments and accounts receivable. The Company’s cash, cash equivalents and investments are held in accounts with financial institutions that management believes are creditworthy. The Company’s investment policy includes guidelines on the quality of the institutions and financial instruments and defines allowable investments that the Company believes minimizes the exposure to concentration of credit risk. These amounts, at times, may exceed federally insured limits. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. Accounts receivable primarily consist of amounts due under strategic partnership and other license agreements with major multi-national pharmaceutical companies for which the Company does not obtain collateral.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"></font></div></div>
CY2019Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of the financial statements in accordance with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and the related disclosures at the date of the financial statements and during the reporting period. Significant estimates are used for, but are not limited to, revenue recognition; deferred tax assets, deferred tax liabilities and valuation allowances; fair value of stock options and various accruals. Management evaluates its estimates on an ongoing basis. Actual results and outcomes could differ materially from management’s estimates, judgments and assumptions.</font></div></div>

Files In Submission

Name	View Source	Status
0001583648-19-000021-index-headers.html	Edgar Link	pending
0001583648-19-000021-index.html	Edgar Link	pending
0001583648-19-000021.txt	Edgar Link	pending
0001583648-19-000021-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
pirs-20190331.xml	Edgar Link	completed
pirs-20190331.xsd	Edgar Link	pending
pirs-20190331_cal.xml	Edgar Link	unprocessable
pirs-20190331_def.xml	Edgar Link	unprocessable
pirs-20190331_lab.xml	Edgar Link	unprocessable
pirs-20190331_pre.xml	Edgar Link	unprocessable
pirs3-31x19ex311.htm	Edgar Link	pending
pirs3-31x19ex312.htm	Edgar Link	pending
pirs3-31x19ex321.htm	Edgar Link	pending
pirs3-31x19ex322.htm	Edgar Link	pending
pirs3-31x201910xq.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PIRS
PIERIS PHARMACEUTICALS, INC. Stock $pirs

2019 Q2 Form 10-Q Financial Statement

#000158364819000021 Filed on May 10, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PIRS PIERIS PHARMACEUTICALS, INC. Stock $pirs

2019 Q2 Form 10-Q Financial Statement

#000158364819000021 Filed on May 10, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PIRS
PIERIS PHARMACEUTICALS, INC. Stock $pirs